Other Income & Expense

Derivative Gain (Loss) Excluded from Effectiveness

Kailera Therapeutics Derivative Gain (Loss) Excluded from Effectiveness increased by 241.3% to $5.72M in Q1 2026 compared to the prior quarter.

Analysis

StatementIncome Statement
SectionOther Income & Expense
First reportedQ1 2025
Last reportedQ1 2026May 26, 2026
Metric ID: abbv_derivative_gain_loss_excluded_from_effectiveness

Historical Data

2 periods
 Q1 '25Q1 '26
Value$1.68M$5.72M
QoQ Change—+241.3%
YoY Change—+241.3%
Range$1.68M – $5.72M
Avg YoY Growth+241.3%
Median YoY Growth+241.3%

Frequently Asked Questions

What is Kailera Therapeutics 's derivative gain (loss) excluded from effectiveness?
Kailera Therapeutics (KLRA) reported derivative gain (loss) excluded from effectiveness of $5.72M in Q1 2026.